The global rivastigmine transdermal patches market is anticipated to grow at a CAGR of 6.5% during the forecast period (2022-2028). Parkinson’s disease (PD) and Alzheimer’s disease are both neurological conditions caused by neurodegeneration (gradual damage to brain cells). Globally, disability and mortality due to Parkinson’s disease are increasing faster than any other neurological disorder. According to the World Health Organization (WHO), the prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. Further, according to Mayo Clinics, globally around 50 million people suffer from dementia, and between 60% and 70% are estimated to have Alzheimer’s disease. Such diseases have a major impact on the quality of life of both the patient and the caregiver. Given the short life expectancy following a diagnosis of AD, and the progressive nature of the disease, treatments that stabilize symptoms or delay their progression have important benefits on the quality of life for patients and their caregivers. Cholinesterase inhibitors constitute one of the mainstays of treatment for such diseases. However, gastrointestinal side effects, difficulty accessing therapeutic doses, and poor patient compliance have been identified as barriers to effective treatment with these substances.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/rivastigmine-transdermal-patches-market
The rivastigmine transdermal patch provides a viable solution for all such problems as it supports the continuous delivery of drugs through the skin into the bloodstream in a non-invasive way, avoiding the fluctuations in plasma concentration associated with oral administration. It causes reduced side effects and results in easier access to expected target doses. These benefits, along with other practical advantages of the transdermal patch, contribute to enhanced patient compliance and therefore continuously evolve popular among health providers and caregivers of patients.
On April 12, 2022 — Luye Pharma Group announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration has accepted the Marketing Authorization Application for the company’s investigational Rivastigmine Twice Weekly Transdermal Patch indicated for treating Alzheimer’s disease of mild to moderate symptoms. The product has already received marketing authorization in multiple European countries.
In May 2022, the World Health Assembly endorsed the Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031. The action plan will address the challenges and gaps in providing care and services for people with epilepsy and other neurological disorders such as PD that exist worldwide and ensure a comprehensive, coordinated response across sectors.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Amneal Pharmaceuticals Inc., Luye Pharma Group, Novartis International AG, Ono Pharmaceutical Co., Ltd., and Zydus Healthcare Ltd.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Rivastigmine Transdermal Patches Market Report by Segment
By Type
- 4.6mg/24hr
- 9.5mg/24hr
- 13.3 mg/24hr
By Application
- Alzheimer’s Disease
- Parkinson
- Others
A full report of Rivastigmine Transdermal Patches Market is available at: https://www.omrglobal.com/industry-reports/rivastigmine-transdermal-patches-market
Rivastigmine Transdermal Patches Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie Inc.
- Acino International AG
- Alvogen
- Amneal Pharmaceuticals LLC.
- Mylan N.V.
- NorthStar Rx LLC
- SinSin Pharmaceutical Co., Ltd.
- Sparsha Pharma International Pvt Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
